HIV/AIDS

LEARNING OUTCOMES
 1.Analyse HIV virus life cycle and immunology.
 2. Evaluate risks associated with exposure to
HIV/AIDS-Attitude change training.
 3. Demonstrate a positive attitude towards
HIV/AIDS management. Behavior Change
Communication (BCC) .
 4.Integrate counseling approaches – individual,
group.
OBJECTIVES
 Discuss the causes of HIV/AIDS.
 Describe the stages of the HIV/ AIDS disease.
 Discuss the management of HIV/AIDS patients.
 Discuss the effects of HIV/AIDS.
INTRODUCTION TO HIV
/AIDS
 HIV is a public health threat globally. An estimated 1.5
million Kenyans are living with HIV, of whom 1,136,000
were on antiretroviral therapy by December 2017.
 The MOH releases updated HIV prevention and
treatment guidelines in line with emerging evidence
every 2 years. These guidelines are aligned with the
Ministry of Health’s mission of providing the highest
standard of health for all Kenyans and one of the
Government of Kenya’s Big Four Agenda on universal
health coverage.
 HIV testing services (HTS) provides the first critical link to
comprehensive HIV treatment and prevention. Additionally, this
initial step provides opportunities to offer other interventions
such as sexual and reproductive health services, TB screening
and referral, substance abuse screening and referral, information
and referral for voluntary medical male circumcision, pre-
exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP)
and other combination HIV prevention services.
 HIV testing should be voluntary and conducted ethically in an
environment where the five Cs of Consent, Confidentiality,
Counselling, Correct results and Connection (linkage) can be
assured.
DEFINITIONS OF TERMS
 List of Abbreviations and Acronyms
 AIDS- Acquired Immune Deficiency Syndrome
 ART- Antiretroviral Therapy
 HAART- Highly Active Antiretroviral Therapy
 CD4 - Cluster of differentiation 4
 CDC - Centers for Disease Control and Prevention
 DNA - Deoxyribonucleic acid
 HIV - Human Immunodeficiency Virus
 KAIS - Kenya AIDS Indicator Survey
 KDHS- Kenya Demographic Health Survey
 CT
 MSM- Men who have sex with men
 NACC- National AIDS Control Council
 NASCOP- National AIDS and STIs Control Program
 PLHIV- People Living with HIV
 RNA- Ribonucleic acid
 SSRNA- Single Strand Ribonucleic acid
 UNAIDS - Joint United Nations Programme on HIV/AIDS
 WHO -World Health Organization.
CT
 FDC- Fixed Dose Combination
 ISTI - Integrase Strand Transfer Inhibitor
 IRIS - Immune Reconstitution Inflammatory Syndrome
 NNRTI -Non-nucleoside reverse transcriptase inhibitor
 NRTI - Nucleoside reverse transcriptase inhibitor
 NRTI - Nucleotide reverse transcriptase inhibitor
 PI - Protease inhibitor
 PEP - Post-exposure prophylaxis
 PrEP - Pre-exposure prophylaxis
 PWID - People who inject drugs
HISTORICAL BACKGROUND
 The first case of Acquired Immune Deficiency
Syndrome (AIDS) was recognized in 1981 by the
Centre for Disease Control in USA when they reported
rare a lung infection- Pneumocystis jiroveci (carinii)
pneumonia and Kaposis sarcoma in previously
healthy homosexual men and thy later recognized
that the patients were immunosuppressed.
 Between 1983-1984 various people described the
cause of the syndrome as a retrovirus.
 It was given different names e.g. Lymphadenopathy
associated virus, AIDS associated retrovirus, Human T
CT
 However, In 1986 HIV was accepted as the international
designation for the retrovirus and was done by WHO in a
consultative meeting.
 HIV is now known to have originated from a type of
chimpanzee in West Africa. The virus that affects these
chimpanzees (Simian Immunodeficiency Virus, SIV) was most
likely transmitted to humans and mutated into HIV.
 In Kenya the first case of HIV was described in 1984
DESCRPTION OF HIV EPIDERMIC
 HIV is a worldwide pandemic and has entered the 46th year.
 Globally, 34-46 million people are having HIV infection .About
half of these people are between15-24 years.
 SUBSAHARAN AFRICA
 It has a population of about 10% of worlds population. It is a
home to more than 60% of people living with HIV/AIDS. All age
groups are affected but most are young and middle aged . It is
a major cause of morbidity and mortality.
 KENYA
 National HIV preference is 7% between 15-49 years. Women
are more affected than men. Peak age is between 34-44 years
in males
WHAT IS HIV AND AIDS?
 HIV –stands for human immunodeficiency virus , is the virus that
causes AIDS.
 HIV destroys certain types of blood cells known as T- helper cells
or CD4 cells.
 A person can be infected with HIV for many years before any
symptoms occur, and during this time an infected person can
unknowingly pass the infection to others.
 AIDS –is acquired immunodeficiency syndrome , an advanced stage
of HIV infection that occurs when the immune system cannot fight
off infections that the body is normally able to withstand.
 At this stage, the infected person becomes more susceptible to a
variety of infections known as opportunistic infections.
HOW IS HIV
TRANSMITED?
 HIV is spread through three main modes.
 These modes of transmission are as a result of exposure to body
fluids ( blood, semen, vaginal fluids, and breast milk) of infected
individuals.
 Specifically , HIV can be transmitted through:
1. Sexual contact; Vaginal , Anal, Oral.
2. Blood contact; - injections or needles, cutting tools ,
transfusions of blood and blood products , contact with broken
skin ( exposure to blood through cuts or lesions.
3. Mother –to-child transmission.-pregnancy , delivery ,
breastfeeding.
 CT
Transmission Route Percentage (%) of total transmission

Sexual intercourse 70 - 80

Mother - to – child transmission 5 - 10

Blood transfusion 3-5

Injecting drug use 5 - 10

Health care – e.g. Needle stick injury <0.01

DETERMINANTS OF HIV
TRANSMISSION
Distal Determinants Proximal Determinants Immediate
Determinants
• Health systems • Health care seeking • Viral load.
• Cultural practices • Sexual networks. • Presence of STDs.
• Social economic • Substance use. • Nature of sex.
/poverty • Knowledge about HIV. • Concurrent sex
• Political systems • Risky behavior. networks.
• Demography • Use of condoms.
• Male circumcision.
EPIDEMIOLOGY
 HIV is caused by a retrovirus from the lentivirus family that is called human
immunodeficiency virus. The genetic material consists of a single stranded RNA. The
viral particle is spherical in shape with a diameter of 80-100 manometer. There are
two types
 HIV TYPE 1
 It is found worldwide. It is responsible for the pandemic and is easily transmitted
from person to person including mother to child. So far there are many subtypes of
HIV TYPE 1 but the ones in record are A-K
 HIV TYPE 2
 These is mainly found in West Africa , Mozambique, Angola
 It causes similar illness to HIV 1 but is less transmissible.
 It also rarely causes vertical transmission i.e. mother to child.
 It is less aggressive with slower disease progression.
BIOLOGY
 This is the science of the disease and its causative agent.
 There are two types of HIV strains.
 These are further divided into sub-types as indicated in . HIV 1
has four sub- types namely M, N, O and P while type 2 has seven
namely A-G.
 The HIV virus belongs to a family called Retroviruses and a sub-
group lentivirus.
 Retroviruses are a unique group of viruses in that they go
against the conventions of genetics.
 You may have learnt in your high school or college biology that
RNA is made from DNA.
CT
 Retroviruses defy this convention and are able to form DNA
from RNA! The reason for doing this, is to be able to use the
human cell mechanisms.
 Lentiviruses are a sub-group of viruses that are known for
having a long time period between initial infection and the
beginning of serious symptoms.
 This name is drawn from the Christian period, “Lent” that
refers to the long fasting that the faithful undertake.
 Thus, persons who are infected with this virus will be unaware
of the infection and can spread the virus unknowingly.
PATHOPHYSIOLOGY OF HIV
COMPONENTS OF HIV STRUCTURE.
DOUBLE LIPID MEMBRANE
 The virus has a double stranded membrane that is lined by gp17.
 It is strengthened or studded by surface gp120 by transmembrane gp41
 The glycoproteins mediate the entry of the virus into the host cell.

CASPID
 The capsid is made of several proteins but main is gp 24 which forms the membrane within the
capsule area/viral genetic material composed of two identical strands of RNA.
 Viral enzymes include; reverse transcriptase –It converts viral single stranded RNA into double
stranded DNA.
 This is important during duplication since viral DNA is incorporated into host DNA.
 Integrase; it facilitates integration of viral DNA into host DNA.
 Protease; help to processes the newly formed viral proteins to form the new viral particles /
virions.
STRUCTURE OF HIV
LIFE CYCLE OF HIV
BINDING
 This step consists of several interactions between the host cell
and the virus.
 The first one involves the attachment of the virus through the
gp 120 and gp 41 to the CD4 cell receptor of the host cell.
 Thereafter, there is an interaction between a CD4 cell co‐
receptors and the gp120 complex.
 This step is the most important one in the process, without
which no infection occurs. This works like a key and a lock.
 It is also important to remember this as one of the sites for
medicines called co-receptor antagonists.
FUSION AND ENTRY
 This step involves the fusion of the membranes of the
host cell and that of the virus.
 As noted in the figure above and expounded in , this
step is the target of drugs such as enfurvitide.
REVERSE TRANSCRIPTION
 By now you should have realized that the virus has
uncoated itself by engaging in the last two steps and
only the nucleus and its contents (RNA, reverse
transcriptase, integrase, and other viral proteins)
enter the host cell cytoplasm.
 Using one of its enzymes, reverse transcriptase, the
virus is able to transform from a SSRNA to a dsDNA.
 Can you think of the reason why this virus takes up
the DNA state?
INTEGRATION
 We have all heard of the adage that when you go to Rome you do
what the Romans do!
 The HIV virus having taken a DNA status is in a form similar to that
in the host cell’s nucleus: DNA.
 It is thus transported into the host nucleus and integrates into the
host cell DNA. This is aided by the viral enzyme Integrase. Once
this happens, the cell becomes infected permanently until it dies.
 The infected host cell’s mechanisms are taken over by the virus.
As we all know, DNA gives rise to RNA part of which makes
proteins.
 The virus is now able to use the host cell’s transcription.
CT
 mechanisms to make new RNAs and messenger
RNA(mRNA).
 The latter is released into the cytoplasm of the host
cells and translated into long protein complexes, often
known as polypeptide chains.
 The polypeptides are broken further into the
constituent proteins and enzymes that were discussed
in the biology sub‐section. The other RNAs become the
genomic RNA material that will eventually start off this
cycle again.
VIRAL ASSEMBLY AND BUDDING

 The second last step is the assembly of the proteins,

enzymes and RNAs into virions.
 The RNA and proteins move to the cell surface, and
new immature viruses bud off from the host cell
taking with them part of the host cell’s membrane.
 These budding are said to leave ‘holes’ within the
membrane of the host cell, a factor that contributes
towards the death of the CD4 cells.
VIRUS MATURATION
 The protease enzyme is involved in this final
step by way of releasing individual HIV
proteins.
 You recall that this enzyme also took part in
the protein production step above.
 It thus acts both within the host cell’s
cytoplasm and after release of the virus.
IMMUNE SYSTEM
RESPONSE TO HIV
 Cells of immune system are found in blood and tissue, they
include ;macrophages, neutrophils, Eosinophil's , B-lymphocytes makes
antibodies i.e.
 1. T-helper cells ( CD-4) that helps in communication of immune cells.
 2.T-killer cells (CD-8) that destroys infected cells.
 HIV attacks the immune system. Specifically, it infects cells with the CD4
molecule on their surface.
 The following immune cells have CD4 receptors:
 T-Lymphocytes–CD4+ Cells
 Macrophages
 Monocytes
 Dendritic cells.
 CT
 The most important of these is the helper T cells
(often abbreviated as TH). Helper T cells neither make
antibodies -the job of B cells - nor kill infected cells -
the responsibility of killer or cytotoxic T cells (TC).
Instead, they regulate the proliferation of B cells in
response to the presence of a particular antigen.
 When a TH cells recognizes the presence of the
antigen to which it is attuned, it becomes activated
which begins a process that culminates in B cells
proliferation and antibody production towards that
particular antigen.
IMPLICATIONS ON THE
BODY’S IMMUNITY
 By depleting the population of TH lymphocytes, HIV renders the body
unable to mount an immune response, leaving it vulnerable to a host of
bacterial, fungal, and viral infections (OPPORTUNISTIC
INFECTIONS) .The CD4 + T cell depletion is twofold, that is reduction in
numbers and impairment in function.
 The reduction in the CD4 cell number and the effects on their function
reduces the capacity of the body to fight infectious diseases.
 The hallmark of HIV/AIDS is a profound immunodeficiency as a result of
depletion of CD4+T lymphocytes.
 Once HIV has entered the body, the immune system initiates anti-HIV
antibody and cytotoxic T cell production. However, it can take one to six
months for an individual exposed to HIV to produce measurable quantities
of antibody.
PHASES OF HIV INFECTION
 STAGE 1-Acute infection (Acute sero-conversion Syndrome) –This is the
first stage of HIV infection , when the virus establishes it self in the body.
 Acute sero-conversion syndrome is used to describe the period of time
between when a person is first infected with HIV and when antibodies
against the virus are produced by the body. (usually 6-12 weeks)
 People newly infected with HIV will experience “ flue-like” symptoms,
others do not have any symptoms or are so mild to be noticed.
 This is the window period and the virus is multiplying inside the infected
persons body and can be passed on to others, but the usual HIV test
(antibody test) will produce a false negative report.
 It takes approximately 2-3 months for an infected person to develop
antibodies against HIV after which the test will be positive.
STAGE 2: LATENT OR ASYMPTOMIC
PERIOD(ASYMPTOMIC INFECTION
 Acute stage of HIV infection remains latent (in the body) usually for
a period of to 10 years .
 Throughout this period the person stays infected and infectious,
but is unlikely to be aware of status until he/she has been tested.
 The infected person appears healthy and has no symptoms which
suggest HIV infection.
 The immune response of an infected person is partially able to
suppress the HIV so that the amount of virus in the body and
bloodstream is reduced but not eliminated.
 Through out asymptomatic period there is progressive damage of
immune system as it tries to control the virus.
 CT
 This is demonstrated by a steady decline in the
number of CD4 cells in the blood.
 Some people will have persistently enlarged
nodes or generalized lymphadenopathy.
 Person is infective and the HIV virus can be
detected in various body fluids and lymph
nodes.
 Also ,the antibody can be demonstrated in the
blood stream.
STAGE 3:SYMPTOMIC HIV
DISEASE
 Eventually ,many individuals develop a variety of indicators of
ill health , weight loss and general weakness (asthenia) are the
most common clinical manifestation.
 HIV virus is beginning to affect the immune system.
 Symptoms may include swollen lymph glands , joint and
muscle pains , sore throat, fatigue , fever , night sweats and
diarrhea. Generally ,these symptoms may come and go
intermittently over a period of weeks or months.
 Mucocutaneous manifestations are common e.g. Characterized
generalized papular pruritic eruptions found in 20-60% of
patients with HIV infections, lesions , papule which releases
small drop of fluid when scratched.
 CT
 Recurrent mucocutaneous herpes simplex infections
are found in 5-10 % , over 10% HIV infection
experience varicella Zoster infection.
 Oral candidiasis in the absence of antimicrobial
immuno suppressive therapy or illness is highly
associated with HIV infection
 Its occurrence in an HIV positive patient is often a bad
prognostic sign and an indication of progression
towards “full-blown “ AIDS.
 STAGE 4:AIDS OR LATE HIV
INFECTION
 This is the final stage of HIV infection.
 Acquired - because it is a condition one must acquire or get infected with.
 Immune – it affects the body’s immune system, the part of the body which
fights the germs such as bacteria and viruses.
 Deficiency –it makes the system deficient-not to work properly.
 Syndrome –someone with AIDS may experience a wide range of different
and opportunistic infections
 AIDS occurs when HIV has destroyed vital aspects of the immune system
leaving the body vulnerable to life threatening infections e.g. pneumonia,
tuberculosis, chronic and acute meningitis , kaposis sarcoma, other
neurological syndromes
 WHO CLINICAL STAGING
OF HIV
Stage 1  • Recurrent respiratory tract
infections
• Asymptomatic
 • Herpes zoster
• Persistent generalized
lymphadenopathy.  • Angular cheilitis

Stage 2  • Recurrent oral ulcerations

• Moderate unexplained weight  • Papular pruritic eruptions

loss (< 10% of presumed body  • Seborrheic dermatitis
weight)
 • Fungal nail infections.
 CT
Stage 3
• Unexplained severe weight loss (> 10% of presumed body weight)
• Unexplained chronic diarrhoea for more than one month
• Unexplained persistent fever (intermittent or constant, lasting for >1 month)
• Persistent oral candidiasis
• Oral hairy leukoplakia
• Pulmonary tuberculosis
• Severe bacterial infections (e.g. pneumonia, empyema, meningitis)
• Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis
• Unexplained anaemia, neutropenia and/or thrombocytopenia for more than
one month.
 CT
Stage 4  • Candidiasis of the oesophagus,
trachea, bronchi or lungs
• HIV wasting syndrome (weight
loss > 10%, plus either  • Extra-pulmonary tuberculosis

chronic unexplained diarrhoea or  • Kaposi’s sarcoma

chronic unexplained fever)  • Cytomegalovirus infection

• Pneumocystis pneumonia  • Central nervous system

toxoplasmosis
• Recurrent severe bacterial
pneumonia  • HIV encephalopathy

• Chronic herpes simplex infection  • Cryptococcal meningitis or

for more than one month other extra-pulmonary
cryptococcosis.
 CT
 Disseminated non-tuberculous mycobacteria infection

• Progressive multifocal leuko-encephalopathy

• Chronic cryptosporidiosis
• Chronic isosporiasis
• Disseminated mycosis
• Recurrent non-typhoid salmonella septicemia
• Lymphoma
• Invasive cervical carcinoma
• Atypical disseminated leishmaniasis
• Symptomatic HIV-associated nephropathy or HIV-associated
Cardiomyopathy.
VCT-VOLUNTARY
COUNSELING TESTING
 It is the process by which a person seeks to find out whether she
/he is infected with HIV or not.
 A) VCT is voluntary:-
 VCT services are allowed always voluntary and strictly
confidential.
 The dignity of the client is carefully maintained.
 The client receive complete information about HIV/AIDS.
 CLIENT gives informed consent for the test to be done.
 Counselor's make sure that the client is requesting the service
without any coercion.
 CT
 B)VCT provides professional counseling:
 Profession counseling is a confidential dialogue between the client and the
care provider , with the aim of enabling the client to cope with stress and to
take personal decision related to HIV/AIDS.
 Counseling help the client decide if they are really ready to take the test and
receive the result this help them understand the results.
 Counseling helps the clients develop a plan to reduce future risk of infection.
 C) VCT includes HIV testing:
 HIV testing is done in all VCT centres.
 Results are ready within a short (15-20min) the same day.
 Simple and rapid test are done in most VCT CENTRES.
 CT
 ALL positive results are confirmed within a second test.
 Its done by a trained counselor or lab technique.
 VCT is at the Centre of HIV prevention and care.
 PURPOSE OF VCT.
 To know ones HIV status.
 Help reduce risky behaviour.
 Enable early referrals for appropriate health services.
 Help client plan a future.
 Reduce transmission of HIV.
 Types of HIV testing :- VCT,DCT,RTC-Routine counseling and testing , MCT-
Mandatory counseling and testing, surveillance testing.
BENEFITS OF VCT TO HIV
POSITIVE CLIENTS
 Prevention of HIV transmission to loved ones.
 Make informed decisions about marriage, pregnancy and social relations.
 Clients learn about positive living i.e. taking care of ones health in order to
stay healthy and longer:-avoid unprotected sex, good nutrition, follow up
medical care, physical exercises social support, being optimistic.
 Helps client cope with the psychological issues related to HIV especially
stigma.
 Assist disclosure to partners, families and children.
 Ensure early referrals for other services e.g. nutritionist, FP, PMTCT,
treatment of opportunistic infection, ART.
 Refer clients for legal assistance incase of need.
BENEFITS OF VCT TO
NEGATIVE CLIENTS
 Negative results are strong motivator to reduce risky behavior.
 Reduces fear, anxiety and hopelessness associated with past risky
behavior.
 Clients can seek treatment to other health problems without fear.
 Clients can get married and plan pregnancy without doubt and fear.
LABORATORY TESTING
 The purpose is to establish presence of HIV infection.

 The diagnostic tests are two:- serological test-ELIZA.

 Viral detection methods- P24 marker.

 1.SEROLOGICAL TESTS :-

 Are based on antibody-antigen reaction.

 They detect presence of antibodies in the blood

 Only reliable after window period i.e. time between the onset of infection and
appearance of detectable antibodies.
 Are common and widely used.

 Blood and blood serum are the sample used

 The serological test include :-

ELIZA-ENZYME LINKED
IMMUNO-SORBENT ASSAY
 They are both long and rapid –Elisa test used in the diagnosis of HIV
infection.
 Long test are done in the laboratory and takes about 3 days to produce
results.
 Rapid tests are simple and commonly done in the VCT Centre's.
 They produce results in less than 20 min. a test kit from the manufacturer
is used e.g. determine , Unigold e.t.c
 CONFIRMATORY TEST:-
 Are used to confirm all the positive test , they are very specific and
sensible even to very low level of antibodies.
 They include :- Western blot , immuno-fluorescent antibody assay.
2.VIRAL DETECTION
METHOD
 Its used to detect viral antigens, the antigen may be viral DNA or RNA or
viral proteins or the viral particles .
 They include :-
 Polymerase chain reaction- PCR
 P24 Antigen Assay.
COMPREHENSIVE CARE
CLINIC - CCC
 It is chronic care clinic that embrace chronic care model of providing health care
services to patients requiring long term care and treatment.
 As you have covered in the introduction, HIV infection has no cure, and treatment
is life-long. With HAART, persons infected with HIV can live long and productive
lives; it is our onus as health care workers to support their care and treatment in a
comprehensive manner to help them live long, healthy and productive lives. The
key focus is to:-
 Promote- Promote healthy living (better diet, more physical activity and tobacco
cessation) and healthy societies, especially for the poor and those living in
disadvantaged populations.
 Prevent: Prevent premature deaths and avoid unnecessary disability due to
chronic diseases. The solutions exist now, and many are simple, cheap and cost
effective.
 Treat- Treat chronic diseases effectively, using latest available knowledge. Make
treatment available to all, especially those in the poorest settings.
 Care -Help provide appropriate care by facilitating equitable and good quality
COMPONENTS OF THE
CHRONIC CARE MODEL
 Health system-organization of Health care: Visible support of improvements
provided by senior leadership . Incentives for care providers.
 Self-management Support:- educational resources, skills training and
psychosocial support provided to patients to assist them managing their own care.
 Decision Support :Wide dissemination of practice guidelines. Educational
specialists support provided to healthcare team.
 Delivery System Design: Planned visits and sustained follow-up. Clearly define
roles of healthcare team.
 Clinical Information Systems: Surveillance system that provides alerts, recall
and follow-up information.
 Community Resources and Policies: Identify effective programs and encourage
appropriate participation. Referral to relevant community-based services.
TRIAGE OF PATIENTS IN THE
HIV CLINIC
 Triage- can be defined as the process where treatment of
patients is prioritized based on the severity .The term comes
from the French verb “trier”, meaning to separate, sift or
select.
 PRINCIPLES OF TRIAGE:-
 Patientsshould be quickly assessed upon arrival at the
Health Facility.
 Assessment should be done by a qualified HCW who can
rapidly classify patients based on severity of illness or
likelihood of deteriorating rapidly.
 Patients identified as requiring urgent medical attention are
seen by a senior HCW immediately before other patients are
IMPORTANCE OF TRIAGE
 Patients who are critically ill or who may deteriorate rapidly (such as young
children) are quickly identified and immediately stabilized. If these patients
wait on the queue they may die before being attended to .
 Triage can be part of the facility infection prevention protocol by identifying
coughing patients who can be seen early or asked to wait in a special well-
ventilated area to reduce air borne disease transmission like TB .
 Triage can enhance task shifting by identifying stable patients who can be
seen by less experienced HCWs e.g. prescription for the drug pick ups .
 Triage can identify patients who need attention at specific departments,
such as pregnant women who may need to be seen at the MCH
PROCESS OF TRIAGE
 Identifying patients who need to be seen urgently
 Documenting the triage findings
 Providing urgent medical management for the priority patient.
 MANAGEMENT OF HIV
CLINIC
Activities that take place in  Manager .
HIV clinic:-  Leader.
 Patient education .
 Lifelong learner / Researcher.
 Triage of patients.
 Teacher.
 Provision of medication.
 Strategies in managing HIV
 Health care providers who are clinic
seven star professionals:-  Relevance
 Care giver.
 Quality
 Decision maker.
 Cost effectiveness.
 Communicator.
 Equity .
ROLE OF THE NURSE IN HIV
CLINIC
 Triage patients.
 Continuation of clinical care of stable patients.
 Nursing care.
 Adherence counseling.
 Detection of side effects and adverse effects of
medication.
MANAGEMENT OF HIV
INFECTION
 CLINICAL SUPPORT:-  NON –CLINICAL:-
 Management of opportunistic infections
 Spiritual support.
and conditions.
 Antiretroviral therapy  Psychosocial support .
 Opportunistic infections.  Emotional support.
 The occurrence of an OI depends on
 Human Rights and Legal support.
both.
 Rate of progression of HIV infection.  Physical .
 Extent of suppression of immune system.  Social .
 Management of opportunistic infections
and conditions.
 NB: The main burden of disease in
PLWHIV is from opportunistic infections.
CT
 NUTRITIONAL INTERVENTIONS
 Identify available, accessible healthy foods.
 Counsel and/or plan a diet with a patient taking into consideration the
following issues.
 Recommended additional energy intake.
 Encourage a healthy diet.
 Promote food safety.
 Drug –food interaction.
 Special concerns – pregnancy, children.
STANDARD PACKAGE OF CARE FOR
PLWHIV-8 COMPONENTS OF CARE
 Antiretroviral therapy.
 Positive Health ,Dignity and Prevention.
 Screening for and prevention of specific opportunistic
infections.
 Reproductive health services.
 Screening for and management of Non-communicable
diseases.
 Mental health screening and management.
 Nutrition services.
 Prevention of other infections.
 COMPONENTS OF THE STANDARD
PACKAGE OF CARE FOR PLHIV
Component of Standard Package of Care Subcomponents

1. Antiretroviral therapy (ART)

• Patient preparation
• ART
• Monitoring (clinical and laboratory)

2. Positive health, dignity and prevention;

gender-based violence (GBV) and intimate- • Positive health, dignity and prevention
partner violence (IPV) screening; and HIV components o Disclosure
education/counselling o Partner/family testing
o Condom use
o Family planning
o STI screening, prevention, and treatment
o Adherence counselling and support
 CT
3. Specific opportunistic infection
screening and prevention • Cotrimoxazole preventive therapy
• Tuberculosis (TB) o Intensified case
finding
o Isoniazid preventive therapy
o ART for TB/HIV co-infected patients

• Cryptococcal meningitis ( fluconazole

200mg )

4. Reproductive health services

• Sexually transmitted infections
screening and management
• Family planning and pre-conception
services
• Maternal healthcare
• Cervical cancer screening
 CT
5.Non-communicable diseases screening and
management • Hypertension
• Diabetes mellitus
• Dyslipidaemia
• Chronic kidney disease
• Other NCDs

6. Mental health screening and management

• Depression
• Alcohol and drug use/addiction

7. Nutritional services
• Assessment
• Counselling and education
• Management and support
CT
8.Prevention of other infections
• Immunizations
• Malaria
• Safe water, sanitation and hygiene
OTHER ESSENTIAL PACKAGE
OF CARE FOR PLWHIV
 Counselling and psychological support.
 Prevention with positives.
 Co-trimoxazole prophylaxis therapy.
 Tuberculosis prevention and treatment among PLHIV.
 Sexually transmitted and other reproductive tract infections.
 Screening for cervical cancer.
 Preventing Malaria.
 Vaccination and immunization.
 Reproductive Health and Family Planning.
 Nutrition .
 Safe water, sanitation and hygiene.
ANTRETROVIRAL DRUGS
 OBJECTIVES:-
 Define ARVS and state their mode of actions.
 List the major classes of ARVS with examples.
 Describe the mechanism of action for each major
class of ARVS.
 State the standard dosages for first and second line
regimens of the HAART concept.
 Explain the principles of ART treatment.
 State the goals of ART.
 DEFINE ARVS
 ARVS are medicine that reduce the number of
circulating HIV virus(virological goal).
 They prevent the HIV from making new copies of
itself.
 Ensure there’s reduced damage to immune systems
leading to improved immune functioning and delay in
onset of AIDS (immunological goal).
 Enhance quality of life and reduce emergency of
opportunistic infection (therapeutic goal)
 Reduces the impact of HIV transmission in the
 INDICATIONS FOR
ARVS
 Antiretroviral therapy-treatment of infected persons
meeting treatment criteria.
 Prevention of mother to child HIV transmission(PMTCT)
 Post Exposure Prophylaxis (PEP)-prevention of infection
in exposed uninfected person e.g needle stick injury ,
sexual assault.
 Pre Exposure Prophylaxis (PreP)-prevention of infection
in exposed most at risk persons e.g PWID , commercial
sex workers , discordant couples
PRINCIPLES OF ART
TREATMENT
 ART is part of the comprehensive  The choice of drug should
care of HIV infection. take into account:-
 Current ART does not cure HIV
 Efficacy
infection.
 Treatment should be planned and  Dosing schedule.
started in good time.  Affordability .
 Regular follow-up and monitoring
 Availability .
is essential.
 Adherence and compliance is key  Tolerability .
to successful treatment.
 Treatment should be stopped or
changed when necessary .
 GOALS OF ART
 1.Improvement of quality of life –ART is used to prolong and improve
quality of life in people living with HIV VIRUS .Therefore the good of therapy.
 2.Maximal and durable suppression of HIV replication :- viral load is a
measure of viral replication. ARVS drugs should achieve suppression of HIV
replication. Hence a combination of 3 ARV drug from two different classes are
used to achieve the above suppression of HIV replication results in:-
 Stoppage of disease progression.

 Delay in emergency of drug resistance subtype virus.

 3.Restoration and preservation of immunology function:-CD4 count is
the measure of immune status of a person.
 Suppression of HIV replication- prevents CD4 cell destruction by HIV , Allow
CD4 cells to recover both in number and improve function
 CT
 Reduce the risk of opportunistic infection which may weaken the immune
status. Hence there is improved overall function of the immune system.
 This takes time and also the drugs should adhered to.
 With effective ART the median increase is CD4 count is 100 to 150 cells
per year.
 CD4 count in patients on ART should be monitored after every 6months.
 4.Reduction of HIV related morbidity and mortality:-This is
evidenced by decrease hospitalization, decreased risk of illness, reduction
of all opportunistic , inflammation and malignancies, reduction of HIV
related deaths. Ability to return to work and live a longer more productive
life.
CLASSIFICATION OF ARV
DRUGS
 Major classes of ARVS:-
 Reverse Transcriptase Inhibitors (RTIs)- Nucleoside
Reverse Transcriptase inhibitors (NRTIs) , Nucleotide
Reverse Transcriptase Inhibitors (NtRTIs) , Non-
nucleoside Reverse Transcriptase Inhibitors.
 Protease inhibitors (PI)
 Fusion inhibitors.
 Integrase inhibitors
TARGETS OF ARV DRUGS
 CT
 Antiretroviral drugs are combined to achieve good results.
 The drugs are grouped into three different classes according to how they
work on the HIV virus.
 They have been found to provide Highly Active Anti-retroviral Therapy.
 Reverse Transcriptase Inhibitors:-
 NRTIs inhibit reverse transcription by competitively blocking reverse
transcriptase enzyme activity due to their resemblance in structure to the
viral nucleosides i.e it sits on the active site of the enzyme receptor . Form
the back bone of the ART regimen.
 NtRTIs work in the same way as the NRTIs but differ in chemical structure.
NtRTIs already has a phosphate group but NRTIs get phosphorylated in the
ABBREVIATIONS &NAMES OF
ARVS
 3TC – Lamivudine  EFV – Efavirenz.
 ABC – Abacavir.  ETR – Etravirine.
 ATV – Atazanavir  FTC – Emtricitabine.
 ATV/r –Atazanavir/ritonavir  LPV – Lopinavir.
 AZT –Zidovudine.  LPV/r – Lopinavir/ritonavir.
 DRV – Darunavir.  NVP – Nevirapine.
 DRV/r – Darunavir/ritonavir.  RAL – Raltegravir.
 DTG – Dolutegravir.  RTV- Ritonavir.
 TDF – Tenofovir Disoproxil
Fumarate.
EXAMPLES OF NRTIS &
NTRTIS
GENERIC NAME ADULT DOSAGE PEDIATRIC DOSAGE
Stavudine d4T 30mg BD 1MG/KG BD
Lamivudine 3TC 150mg BD/300mg OD 4mg/kg BD
Zidovudine AZT or ZDV 300mg BD 180-240mg/m2
Didanosine ddi 125mg BD and 200mg BD 120 mg /m2 BD
for <60kg and >60kg
respectively
Abacavir ABC 300mg BD/600mg OD 8mg /kg BD
Tenofovir TDF 300mg OD Not recommended .
It causes decreased bone
marrow density for
children and
adolescents<18years
 NNRTI
GENERIC NAME ADULT DOSAGE PAEDIATRIC DOSAGE
Nevirapine NVP 200mg OD for 2 weeks then 120-160 mg /m2 OD for weeks
200mg BD then BD
Efavirenz EFV 600mg OD
Efavirenz dosages for children As per kg weight dosages
Avoid fatty meals with EFV –
Increases absorption by 50%
ETR – Etravirine.

Dilaviirdine 600mg BD

NNRTI –work by binding

directly on to reverse
transcriptase preventing the
conversion of RNA to DNA and
this stops HIV production
PROTEASE INHIBITORS
 Works at the last stage of the virus reproduction cycle.
 They prevent HIV virus from being successfully assembled and released.
 Inhibits the cutting down of the core multi-protein molecule to functional
viral protein molecules essential for HIV replication.
 Enzymes , core proteins , envelop proteins regulatory proteins
 Enzymes and building block proteins are needed to make complete copies
of the virus which can infect the cells.
 ATV/r –Atazanavir/ritonavir , LPV – Lopinavir , DRV – Darunavir , RTV-
Ritonavir.
 EXAMPLES OF PIS
GENERIC NAME ADULT DOSAGE PEDIATRIC DOSAGE
Indinavir IDV 800mg TDS
Liponavir/ritonavir 400mg/100mg BD <15KG=12mg LPV/kg
LPV/r >15kg = 10mg LPV/kg
Twice daily
Ritonavir RTV 200/400mg
daily(booster dose)
or 600mg BD
Saquinavir SQV/r 600mg
tds/1000mgbd
1200 MG TDS
Amprenavir/ 1400mg BD
Fosaprenavir
(fosamprenavir)
Atazanzvir ATV/r 400mg OD
Nelfinavir 750mg-1200mg BD
ENTRY & FUSION
INHIBITORS
 Prevent HIV from entering healthy CD4 cells, most of them are
still being investigated.
 The only drug marketed in this category is ENFURVITIDE.
 It is provided as a powder to be reconstructed before
subcutaneous injection once daily. NOT feasible for public
health use.
 Very expensive , used as salvage therapy.
 Anew fusion inhibitor is MAROVERIC .Not yet in use.
 Block entry of virus into the host CD 4 receptors, dendritic
cells , monocytes , T-lymphocytes.
INTEGRASE INHIBITORS
 Inhibit the integrase enzyme which is responsible for integration of the virus DNA .

 RALTEGRAVIR –recently approved for use by food and drugs association FDA and registered in
Kenya by PPB pharmacy and poisons board.
 DOLUTEGRAVIR (DTG) -

 ≥ 15 years (or ≥ 35 kg body weight): DTG 50 mg once daily, preferably as a morning dose .

 DTG is preferred in first line ART in combination with two other ARVs for adolescents and
adults. DTG is not recommended for women and adolescent girls of childbearing potential.
 NB- HAART is the Gold standard, it is a combination of three or more ARVs in the treatment of
HIV infection:
 Ensures maximal effect on suppressing the virus.

 Ensures prolonged effect.

 Delays emergence of drug resistance

 These ARVs work in different ways to prevent the HIV from multiplying and infecting new cells.
RECOMMENDED HAART
REGIMENS
 Drug combination from different classes.
 2 NRTIs/NtRTI +NNRTI
 2NRTIs + 1PIs
 2 NRTIs/NtRTI+ 2PIs
 3NRTIs (one drug must be ABC)
 All individuals with confirmed HIV infection are eligible for
ART ,irrespective of CD4 count , WHO clinical stage , pregnancy or
breastfeeding status , co-infection status , risk group or any other criteria
provided that the client is willing and ready to take ART and adhere to
follow –up recommendations.
 ART should be started in all patients as soon as possible preferably within
2 weeks of confirmation of HIV status.
CT
 Preferred first-line ART for infants , children ,
adolescents and adults - :
 Birth to 4 weeks; AZT+3TC+NVP
 4 weeks<3years:ABC+3TC+LPV/r
 3-14Years(and <35kg body weight):ABC+3TC+EFV.
 > 15 years(or>35kg body weight):TDF+3TC+DTG(or
TDF+3TC+EFV for women and adolescent girls of
childbearing potential).
BENEFITS OF ART
 Allows CD4 cells to increase and strengthen the immune system .
 Prevents multiplication of virus.
 Reduces incidences of opportunistic infections.
 Improves quality of life.
 Decreases morbidity and mortality.
PREVENTION OF MOTHER TO
CHILD HIV TRANSMISSION (PMTCT)
 The National PMTCT program has embarked on a 5-year (2011-
2015) plan to eliminate MTCT. Elimination for this purpose is
defined as a MTCT transmission rate of Elimination for this
purpose is defined as a MTCT transmission rate of <5%
(UNAIDS)
 The elements of the elimination plan include:
 i. Health services delivery strengthening
 ii. Community participation strengthening
 iii. Effective partnerships and advocacy
 iv. Tracking progress
CT
 The plan emphasizes on collective responsibility for
all community programs and healthcare workers to
ensure that:
 All pregnant women in the community attend early
ANC and are tested for HIV .
 All health facilities deliver full ART as the PMTCT
regimen of choice to HIV positive pregnant women
 All HIV positive women and their infants receive
chronic longitudinal care
4-PRONGS OF PMTCT
 The 4 prongs are:
 Primary prevention of HIV: supporting women to remain HIV
negative before and during pregnancy as well as during lactation
 Prevention of unwanted pregnancies: all women of
reproductive age including HIV positive women have access to
effective family planning services
 Prevention MTCT of HIV among infected women: using
recommended interventions for the HIV positive mother and for the
exposed infant
 Chronic care, treatment and follow up: for HIV infected
women, the exposed and infected infants and other family members
ARVS FOR POST-EXPOSURE
PROPHYLAXIS (PEP)
 PEP should be offered as soon as possible (< 72 hours) after high risk
exposure
The recommended ARV agents for PEP are o 0-14 years (and < 35 kg): ABC
+ 3TC + LPV/r o ≥ 15 years old (or ≥ 35 kg): TDF + 3TC + DTG (or TDF +
3TC + ATV/r for women and adolescent girls of childbearing potential)
ORAL PRE-EXPOSURE
PROPHYLAXIS (PREP)
 Oral PrEP should be offered to HIV negative individuals at
substantial ongoing risk of HIV infection (including the
seronegative partner in a discordant relationship)
 The recommended ARV regimen for use as PrEP is: TDF (300
mg) + FTC ( 200 mg) once daily.
 PrEP does not eliminate the risk of HIV infection and it does
not prevent STIs or unintended pregnancies.
 PrEP should only be offered after assessment to establish
eligibility, readiness for effective use, required follow-up
(including HIV testing every 3 months) and absence of
contraindications to TDF and/or FTC .
NATIONAL TREATMENT
GUIDELINES.
 Guidelines are set to help standardize care and support clinical decision.
 The guidelines change from time to time as a result of :-
 Availability and accessibility of new drugs.
 Development of drug resistance.
 Advancement in treatment and care.

NB – Risk of resistance and failure is high with use of mono or dual therapy.
Fixed dose combination (FDC) are preferred formulations for they reduce
pill burden and increases level of adherence to treatment.
GUIDELINES ON USE OF ANTIRETROVIRAL DRUGS FOR TREATING
AND PREVENTING HIV IN KENYA; 2018 EDITION.
PSYCHOSOCIAL CARE &
COUNSELLING
 INDIVIDUAL /GROUP COUNSELLING
 Psychosocial Concerns at Different Level:
 At Individual level;
 Self- stigmatization and isolation
 Poor parenting
 Caring for HIV infected parents and siblings
 Separation and isolation from sibling and other family members
 Chronic illness
 Death or sickness of the parents
 Loss of home and property
AT FAMILY LEVEL;
 HIV illness in multiple family members
 Poverty
 Stigma and discrimination
 Multiple losses
 Dysfunction al relationship
 Single parenting
 Child headed house holds
 Elderly care givers chronic illness e.g. hypertension, diabetes and arthritis
 Death and bereavement
AT COMMUNITY LEVEL:
 Lack of knowledge on HIV
 Lack of knowledge of children’s need worsening poverty
 Stigma and discrimination
 Increased numbers of orphans and vulnerable children
 Peer influence
PRIMARY PREVENTION OF
HIV INFECTION
 Prevention HIV infection comprises of 7key elements/ Strategies
 These are:-
 Behavioral interventions- the ABC (abstinence , Be faithful , condom ,
condom use ) prevention strategy.
 HIV testing and counselling , using individual risk as the basis for counselling.
 Voluntary Medical Male Circumcision (VMMC)
 Health facility HIV prevention.
 Treatment of sexually Transmitted infections (STIs)
 Community engagement in HIV prevention.
 ART for MTCT and HIV prevention.
COUNSELING AND
PSYCHOSOCIAL SUPPORT
 Mitigation of fear, anger, self-stigma and discrimination,
 Alleviation of grief, bereavement and stress among partners and family members,
 Behaviour change in support of healthy living and prevention of further HIV
transmission,
 Disclosure and partner’s notification, and age appropriate disclosure for children
 Family/partner counselling to identify family members, who may need care and
treatment,
 Skills-building on how to live a healthy and productive life,
 Identification and treatment of depression and substance abuse. Mental illness and
substance and alcohol dependence are common conditions among PLHIV. These
conditions, besides affecting the quality of life of patients can cause non-
adherence to prophylactic and ART regimens as well as undermine safer sex
practices; and
EVIDENCE BASED
BEHAVIORAL INTERVENTIONS
 ABC approach.
 Reduction of sexual partners.
 Delay sexual debut.
 Control of alcohol consumption and substance abuse.
 In your opinion what are some of the social cultural factors that influence
behavior change adoption.
 Stigma , HIV status , Gender inequality , substance use.
 Power dynamics .
 Multiple partners and concurrent partnerships.
 Social-cultural norms.
 Legal factors.
 Cultural issues e.g. wife inheritance.
OPPORTUNISTIC INFECTIONS
 These are infections/conditions which manifest when a person is
immunosuppressed.
 Common Ois include:
 Bacterial infections-systemic, respiratory and skin infections eg pneumonia ,
TB, PCP, Non typhi salmonella e.t.c
 Fungal infections-systemic and cutaneous infections e.g candidiasis ,
cryptococcosis, histoplasmosis , aspergillosis.
 Parasitic infections-toxoplasmosis , cryptosporidiosis , microsporidiosis.
 Viral infections – herpes simplex , varicella zoster , cytomegalovirus ,
hepatitis A,B etc.
 HIV related malignancies – kaposi’s sarcoma ,primary CNS lymphoma ,
carcinoma of the cervix , other lymphomas.
PRINCIPLE OF MANAGEMENT
OF OIS
 Identification and diagnosis.
 Treatment ;general , symptomatic specific.
 Adherence to treatment is key to success of any disease condition.
 All patients need support to adhere and complete treatment.
 Treat Opportunistic infections first where applicable.
 Introduce ART when patients has tolerated the treatment and ready to take
more pills.
 Always enquire about side effects and offer appropriate advice on the
same.
 NB: opportunistic infections cause vast majority of morbidity and mortality
associated with HIV.
CT
 Most are readily treatable and /or preventable.
 Most of these treatment are available , simple and affordable.
 Duration of treatment is usually short except TB which takes 6 months.
BEHAVIOR CHANGE
COMMUNICATION (BCC)
 Behavior change communication (BCC) is an interactive process with communities (as
integrated with an overall program) to develop tailored messages and approaches
using a variety of communication channels to develop positive behavior's ;promote
and sustain individual, community and societal behavior change.
 In context with HIV/AIDS BCC is an essential part of a comprehensive program that
includes both services(medical , social, psychological and spiritual) and commodities
( condoms , needles and syringes).
 Both individuals and communities can reduce their level of risk or change behaviors
after understanding basic facts about HIV and AIDS.
 Adopt key attitudes , learn a set of skills and be given access to appropriate products
and services.
 They must also perceive their environment as supporting behavior change and the
maintenance of safe behaviors, seeking appropriate treatment for prevention , care
and support.
ROLE OF BEHAVIOR CHANGE
COMMUNICATION
 Effective BCC can :

 Increases knowledge – BCC can ensure that people are given the basic facts
about HIV and AIDS in a language or visual medium or any other medium that
they can understand.
 Stimulate community dialogue – encourage national discussion on the basic
facts of HIV , the underlying factors to the epidemic , such as risk behaviors ,
environments and cultural practices related to sex and sexuality and practices
such as drug use. It can also stimulate discussion of healthcare seeking
behaviors for prevention , care and support.
 Promote essential attitude change – e.g. perceived personal risk of HIV infection
, belief in the right to and responsibility for safe practices and health supporting
services , compassionate and non-judgmental provision of services, greater
open-mindedness concerning gender roles and increasing basic rights of those
vulnerable to affected by HIV and AIDS.
CT
 Reduce stigma and discrimination- communication about HIV prevention and AIDS
mitigation should address stigma and discrimination and attempt to influence social
responses to them.
 Create a demand for information and services – BCC ca spur individuals and
communities to demand information on HIV/AIDS and appropriate services.
 Advocate - can lead policymakers and opinion leaders toward effective approaches to
the epidemic.
 Promote services for prevention , care and support. – BCC can promote services for
STIs , IDUs , orphans and vulnerable children , voluntary counseling and testing for
mother to child transmission , support groups for PLHA; clinical care for opportunistic
infections , social and economic support.
 Improving skills and sense of self –efficacy – BCC programs can focus on teaching or
reinforcing new skills and behaviors such as condom use , negotiating safer sex , safer
injecting practices . It can contribute to development of a sense of confidence in
making and acting on decisions
 THE PROCESS OF BEHAVIOR
CHANGE
Stages of behavior change Enabling factors channels
continuum
Unaware Providing effective Mass media
communication
Aware
Concerned Creating an enabling Community networks and
environment – policies , traditional media
community values , human
rights
Knowledgeable
Motivated to change
Practicing trial behavior Providing user-friendly , Interpersonal / group
accessible services and communication.
commodities
Practicing sustained behavior
change
BCC GOALS
 Increase condom use.
 Increase appropriate STI care seeking behavior.
 Delay sexual debut.
 Reduce number of partners.
 increase perception of risk or change attitudes towards use of condoms.
 Increase demand for services.
 Create demand for information on HIV and AIDS.
 Create demand for appropriate STI services
 Interest policymakers in investing in youth –friendly VCT services.
 Promote acceptance among communities of youth sexuality and the value of
reproductive health services for youth.
GUIDING PRINCIPLES
 BCC should be integrated with program goals from start – it is an essential element of HIV
prevention , care and support programs , providing critical linkages to other program
components , including policy initiatives.
 Formative BCC assessments – must conduct to improve understanding of the needs of target
populations , barriers , support for behavior change.
 The target population should participate in all phases of BCC development and in much of
implementation.
 Stakeholders need to be involved from the design stage.

 Having a variety of linked communication channels is more effective than relying on one
specific one.
 Pre-testing is essential for developing effective BCC materials.

 Planning for monitoring and evaluation should be part of the design of any BCC program.

 BCC strategies should be positive and action-oriented.

 PLHA should be involved in BCC planning and implementation.

STEPS IN DEVELOPING A BEHAVIOR
CHANGE COMMUNICATION
 State program.  Develop communication products.
 Involve stakeholder.  Pretest.
 Identify target populations.  Implement and monitor.
 Conduct formative BCC  Evaluate .
assessments.  Analyze feedback and revision.
 Segment target populations.
 Define behavior change
objectives.
 Design BCC strategies and
monitoring and evaluation plan.
CHALLENGES TO BCC
PROGRAMS
 BCC versus IEC –INFORMATIONEDUCATION,COMMUNICATION in practice , production of
discrete communication materials.
 Integrating BCC in all programs – it is a component of all successful interventions but in
reality it is not included in their original design.
 Limited training resources –limited capacity and availability of trained , advertising
agencies and media outlets.
 Political and physical environments- geography and populational diversity can complicate
the development of BCC programs.
 Sustainability .
 Expanding the response- to have a real impact on the epidemic , responses must be
expanded in quality , scope of activities and geographic coverage.
 Budgets .
 Linkages and coordination –for BCC to be effective , their messages and information should
be coordinated , building and maintaining linkages.
ATTITUDE CHANGE TRAINING.

 EVALUATE RISKS ASSOCIATED WITH EXPOSURE TO HIV/AIDS:-

 What is the criteria of being at risk/not at risk of HIV/AIDS?
 What do you understand by the term ‘’exchange of fluids’’.
 What are some of the sensitive issues related to sex?
 What factors prevent people from talking about the risks of having sex?
 Identify some of the gender issues involved in HIV/AIDS transmission.
 What specific information should be communicated about HIV/AIDS?
 Identify cultural practices ,attitudes and beliefs towards HIV/AIDS.
 State the ethical issues related to disclosure of HIV status.

GROUPS DISCUSSION AND PRESENTATION

UNIT SUMMARY QUESTIONS
 Outline the main mode of HIV/AIDS  Outline the goals of ART therapy.
transmission.
 State the benefits of ART therapy.
 Describe the implication of HIV
infection to immune system.  Outline the indications of ARVs.
 Describe the HIV virus replication  State the importance of triage in
cycle (life cycle). HIV management.
 Identify the cells that have CD4
 Describe the role of the nurse in
receptor in the body.
HIV management.
 Define HAART.
 Discuss the effects of STIs
 State the areas of ARVs target in the
infections in HIV disease
HIV life cycle. progression.
 State the recommended ARVs
regimen and their classifications.
CT
 State Standard package of Care for PLWHIV-8 components of care.
 Explain the impact of HIV/AIDS infection on the following:

a) family
b) Community
c) Health care system
 Describe the key primary prevention strategies of HIV in Kenya.
 Define PMTCT.
 Outline the 4 prongs of PMTCT.
 Explain behaviour change communication
 Outline the role of behaviour change communication (BCC)
REFERENCES AND FURTHER READING

 Kenya Demographic and Health Survey 2008-09. Ministry of Health,

Republic of Kenya. (2009). Modes of Transmission Study
 Ministry of Health, Republic of Kenya. (2018). Guidelines for Antiretroviral
Therapy in Kenya, 4th Edition.
 National AIDS Control Council, Office of the President, Kenya. (2008).
UNGASS 2008 Country Report for Kenya, 3. UNAIDS 2013 Global Report
 National HIV training curriculum modules (NHITC) Ministry of Heath.
 Fundamentals of Global HIV Medicine. AAHIVM 2009. Z Temesgen
 Kenya National Manual for the Management of HIV-Related Opportunistic
 Infections and Conditions (Ministry of Health),2008
 Medical Management of HIV Infection. 15th edition 2009-2010. Bartlett
 Sanford guide to anti-microbial therapy of HIV 2010
CT
 Antenatal Clinic Sentinel Surveillance
2010:https://www.google.co.ke/search?biw=1366&bih=609&noj=
1&sclient=psyab&q=ANC+sentinel+surveillance+2010&oq=ANC
+sentinel+surveillance+2010&gs_l=serp.12...40188.64642.1.6641
3.54.42.6.5.5.4.2421.17191.11j5j5j4j6j1j5j3j0j1.41.0....0...1c.1.44.
serp..23.31.4313.DvwGuXXVaVE#
 National PMTCT Guidelines 4th edition 2012, Nairobi, Kenya
National HIV Care and Treatment guidelines 4th Edition 2011,
Nairobi, Kenya